The impact of montelukast combined with Ketotifen on the levels of serum TGF-β1 , MCP-1, SDF-1 in asthma suffe- rers

WANG Xinhua; HAN Shuguang; LV Lei; ZHAO Hongqing

doi:10.3969/j.issn.1671-6450.2016.03.011

Abstract：Objective To investigate the impact of montelukast combined with Ketotifen on the levels of transforming growth factor-β1(TGF-β1), monocyte chemoattractant protein-1 (MCP-1), stromal cell derived factor-1 ( SDF-1) in asthma sufferers.Methods 128 cases of asthma patients in Department of Respiration, Wuxi Second People's Hospital Affiliated to Nanjing Medical University from October 2014 to October 2015 were selected and randomly divided into observation group (n =64) and control group ( n =64).Patients of two groups were given symptomatic treatment;patients of the observation group were treated with montelukast combined with Ketotifen orally, while patients of the control group were treated with mon-telukast orally, and both for three months.The levels of TGF-β1 , MCP-1, SDF-1 of two groups before and after treatment were compared.Results The total effective rate of observation group( 96.9%) were higher than control group (84.4%) ( P <0.05).The Asthma Control Test table (ACT) score of observation group (24.25 ±3.98) was significantly higher than control group (20.12 ±4.02) ( P <0.05).The levels of expiratory volume in one second (FEV1) and peak expiratory flow rate (PEF) of observation group were (80.25 ±4.25)%, (7.25 ±0.69) L/min were higher than control group (75.02 ± 3.96)%, (5.82 ±0.70) L/min ( P <0.05).The levels of serum TGF-β1, MCP-1, SDF-1 of observation group (42.2 ± 6.0) ng/ml, (48.6 ±4.0) ρg/ml, (252.4 ±32.2) ng/L after treatment were lower than the control group (48.9 ±5.2) ng/ml, (59.0 ±4.2) ρg/ml, (425.3 ±40.6) ng/L, the difference was statistically significant ( P <0.05).Conclusion Montelukast combined with Ketotifen can effectively reduce serum TGF-β1 , MCP-1, SDF-1 levels in asthmatic patients and improve clinical symptoms, lung function and improve patient outcomes.